March 2012
Volume 53, Issue 14
Free
ARVO Annual Meeting Abstract  |   March 2012
Effects Of Limited Core Vitrectomy In The Treatment Of Age-related Macular Degeneration
Author Affiliations & Notes
  • Katharina Schramm
    Department of Ophthalmology, Hospital of the Goethe University, Frankfurt, Frankfurt, Germany
  • Frank Heinz Koch
    Department of Ophthalmology, Hospital of the Goethe University, Frankfurt, Frankfurt, Germany
  • Michael Janusz Koss
    Department of Ophthalmology, Hospital of the Goethe University, Frankfurt, Frankfurt, Germany
  • Footnotes
    Commercial Relationships  Katharina Schramm, None; Frank Heinz Koch, None; Michael Janusz Koss, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 2620. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Katharina Schramm, Frank Heinz Koch, Michael Janusz Koss; Effects Of Limited Core Vitrectomy In The Treatment Of Age-related Macular Degeneration. Invest. Ophthalmol. Vis. Sci. 2012;53(14):2620.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the clinical efficacy and safety of an additional core vitrectomy to the standard therapy in patients with exsudative age-related macular degeneration (ARMD).

Methods: : In this prospective, controlled, single-centre study 50 eyes of 50 patients (mean age: 74,1±7,1; median 74 (69/78)) with ARMD were enrolled and randomized 1:1 to group 1 - core vitrectomy additional to three times injections of ranibizumab (3xRbz) or group 2 - 3xRbz (control). In group 1 16/25 eyes (64%) and 12/25 (48%) in group 2 had a posterior vitreous detachment (PVD) prior to study start. Changes in best corrected visual acuity (ETDRS), central macular thickness and macular volume (OCT) as well as the rate of reinjection with an OCT based PRN protocol were monitored prospectively over 48 weeks.

Results: : 47 eyes for completed follow-up at week 48. In group 1, 4/24 were stable within 1 line (16,67%), 3/24 lost more than 1 line (12,5%) and 17/24 gained more than 1 line (70,83%) and improved in average by 9,75 letters. In group 2, 3/23 remained stable within 1 line, 18/23 gained more than 1 line (78,26%) resulting in 14,3 letters.Central macular thickness decreased by 85,5834µm (28,8%) in group 1 and by 121,4347µm (32,68%) in group 2 compared to baseline.In group 1, four patients received three additional and two patients two additional Rbz injections. In group 2, three patients received three additional, three patients two and 12 patients one additional Rbz injections. This yielded in an average injection rate of 3,66 in group 1 and 4,13 in group 2 over 48 weeks.PVD was identified in group 1 in 20/24 (83%) and in group 2 in 13/23 (56%) patients, which was not correlated with any outcome measure. No systemic or ocular adverse events were noticed.

Conclusions: : An initial core vitrectomy combined with a conventional ranibizumab injection regimen for exudative ARMD patients was safe and lead to similar functional results with less intravitreal ranibizumab injections over 48 weeks.

Keywords: age-related macular degeneration 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×